ADVANCED SOLID TUMORS

This was an early-stage study to test the safety and find the right dose of a new cancer drug called PF-07265028. It was given alone and in combination with another immunotherapy drug, sasanlimab, to a small group of people with advanced solid tumors that had stopped responding t…

This early-stage study tested a new drug called ASP2074 in adults with advanced solid tumors that had spread or couldn't be removed by surgery. All participants had already tried all available standard treatments and were no longer benefiting from them. The main goals were to fin…

This early-stage study tested a new oral drug called Debio 0123 in combination with the chemotherapy carboplatin. It aimed to find a safe and effective dose for adults with advanced solid tumors that had stopped responding to prior platinum-based treatments. The main goals were t…

This early-stage study tested a new oral medication called ATX-559 in patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the drug behaves in the body. The trial was terminated after enrolling…

This was a first-in-human study to test the safety and find the right dose of a new immunotherapy drug called FAZ053. It was given alone and in combination with another drug, PDR001, to 154 adults with advanced solid tumors that had stopped responding to standard treatments. The …

This early-stage study tested a new oral drug called BGB-30813, both alone and combined with the immunotherapy drug tislelizumab, in people with advanced cancers that had spread. The main goals were to find safe doses and check for early signs that the treatments might help shrin…

This early-stage study aimed to test the safety and find the right dose of a new drug called BLU-222 for people with advanced solid tumors that have stopped responding to standard treatments. It involved about 50 patients with cancers like breast, ovarian, and gastric cancer. The…

This early-stage study tested a new drug called INCA00186, given alone or combined with other immunotherapy drugs, in people with advanced head/neck cancers or certain gastrointestinal cancers. The main goals were to check the safety of the drug, find the right dose, and see if i…

This early-stage study tested a new drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety, how the body processes it, and what side effects it might cause. The trial was termina…

This early-stage trial tested a new drug called SIM0501, both alone and combined with an existing cancer drug (olaparib), in people with advanced solid tumors that had specific genetic changes. The main goal was to check the safety, side effects, and how the drug moves through th…

This early-stage study tested the safety of an experimental drug called INCB081776, both alone and combined with another drug, in people with advanced cancers that had stopped responding to standard treatments. The main goal was to find safe dosage levels and understand how the b…

This early-stage study tested a personalized cell therapy called HV-101 for adults with advanced solid tumors that had returned or spread. Doctors planned to extract immune cells from a patient's own tumor, grow them in a lab, and reinfuse them to fight the cancer. The trial was …